Abstract
Metastasis is the major cause of death in breast cancer patients. In this study, we investigated the effects of baicalin, a natural compound, on cell migration, invasion and metastasis using human breast cancer MDA-MB-231 cell line as model system. Baicalin not only dose-dependently inhibited MDA-MB-231 cells migration and in vitro invasion, but also suppressed the tumor outgrowth and the pulmonary metastasis of MDA-MB-231 cells in xenograft model. Importantly, treatment of baicalin caused little change in body weight, liver and kidney function of recipient animals. Tumorigenesis-inhibitory effect is likely linked to the capability of baicalin to downregulate metalloproteinase (MMP)-2, MMP-9, urokinase-type plasminogen activator (uPA) and uPA receptor (uPAR) expression in MDA-MB-231 cells. As baicalin blocked p38 mitogen-activated protein kinase (MAPK) activity and treatment of p38MAPK inhibitor SB203580 led to the reduction of MMP-2, MMP-9, uPA and uPAR expressions, we concluded that baicalin suppresses the tumorigenecity of MDA-MB-231 cells by down-regulating MMP-2, MMP-9, uPA and uPAR expressions through the interruption of p38MAPK signaling pathway.
Keywords: Baicalin, breast cancer, MDA-MB-231 cell, metastasis, side effects.
Anti-Cancer Agents in Medicinal Chemistry
Title:Baicalin Suppresses Migration, Invasion and Metastasis of Breast Cancer via p38MAPK Signaling Pathway
Volume: 13 Issue: 6
Author(s): Xiu- Feng Wang, Qian- Mei Zhou, Jia Du, Hui Zhang, Yi- Yu Lu and Shi- Bing Su
Affiliation:
Keywords: Baicalin, breast cancer, MDA-MB-231 cell, metastasis, side effects.
Abstract: Metastasis is the major cause of death in breast cancer patients. In this study, we investigated the effects of baicalin, a natural compound, on cell migration, invasion and metastasis using human breast cancer MDA-MB-231 cell line as model system. Baicalin not only dose-dependently inhibited MDA-MB-231 cells migration and in vitro invasion, but also suppressed the tumor outgrowth and the pulmonary metastasis of MDA-MB-231 cells in xenograft model. Importantly, treatment of baicalin caused little change in body weight, liver and kidney function of recipient animals. Tumorigenesis-inhibitory effect is likely linked to the capability of baicalin to downregulate metalloproteinase (MMP)-2, MMP-9, urokinase-type plasminogen activator (uPA) and uPA receptor (uPAR) expression in MDA-MB-231 cells. As baicalin blocked p38 mitogen-activated protein kinase (MAPK) activity and treatment of p38MAPK inhibitor SB203580 led to the reduction of MMP-2, MMP-9, uPA and uPAR expressions, we concluded that baicalin suppresses the tumorigenecity of MDA-MB-231 cells by down-regulating MMP-2, MMP-9, uPA and uPAR expressions through the interruption of p38MAPK signaling pathway.
Export Options
About this article
Cite this article as:
Wang Feng Xiu-, Zhou Mei Qian-, Du Jia, Zhang Hui, Lu Yu Yi- and Su Bing Shi-, Baicalin Suppresses Migration, Invasion and Metastasis of Breast Cancer via p38MAPK Signaling Pathway, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (6) . https://dx.doi.org/10.2174/18715206113139990143
DOI https://dx.doi.org/10.2174/18715206113139990143 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Psoriasin, A Multifunctional Player in Different Diseases
Current Protein & Peptide Science Peroxisome Proliferator-Activated Receptors and their Ligands in Cancer Drug- Resistance: Opportunity or Challenge
Anti-Cancer Agents in Medicinal Chemistry Serial Analysis of Gene Expression in Eukaryotic Pathogens
Infectious Disorders - Drug Targets Molecular Pharmacology and Pharmacogenomics of Artemisinin and its Derivatives in Cancer Cells
Current Drug Targets Role of Flavonoids in Future Anticancer Therapy by Eliminating the Cancer Stem Cells
Current Stem Cell Research & Therapy CDK1 in Breast Cancer: Implications for Theranostic Potential
Anti-Cancer Agents in Medicinal Chemistry Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area
Current Psychiatry Reviews Glycosides from Medicinal Plants as Potential Anticancer Agents: Emerging Trends Towards Future Drugs
Current Medicinal Chemistry PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?
Current Pharmaceutical Design Antibody Recognition of Fluorinated Haptens and Antigens
Current Topics in Medicinal Chemistry Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer
Current Cancer Drug Targets Polyphenols from Red Wine Modulate Immune Responsiveness: Biological and Clinical Significance
Current Pharmaceutical Design Taurine and the Relevance of Supplementation in Humans, in Health and Disease
Current Nutrition & Food Science History of Autoimmune Pancreatitis and Mikuliczs Disease
Current Immunology Reviews (Discontinued) Natural Product as Substrates of ABC Transporters: A Review
Recent Patents on Anti-Cancer Drug Discovery Cancer Stem Cells – Are Surface Markers Alone Sufficient?
Current Stem Cell Research & Therapy New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Breast Cancer, a Stem Cell Disease
Current Stem Cell Research & Therapy Role of miRNAs in Cancer Diagnostics and Therapy: A Recent Update
Current Pharmaceutical Design FDG-PET/CT Predicts Outcome in Oropharingeal Carcinoma Patients Undergoing Intensity Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes
Current Radiopharmaceuticals